[1]
WHO report on cancer: Setting priorities, investing wisely and providing care for all World Health organization. WHO Organization, 2020.
[2]
World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019., 2020.
[11]
Kumar, N.; Kumar, V.; Chaudhary, Y. A review on synthesis methods of tricyclic 1,2,3,4-tetrahydrocarbazoles. World J. Adv. Res. Rev., 2022, 13(01), 160-171.
[18]
Al-Mohson, A.; Mohammed, Z. Synthesis of novel pyrazole derivatives containing tetrahydrocarbazole, antimicrobial evaluation and molecular properties. Eur. Chem. Commun., 2021, 3(6), 425-434.
[24]
Lang, D.K.; Kaur, R.; Arora, R.; Saini, B.; Arora, S. Nitrogen-containing heterocycles as anticancer agents: An overview. Anticancer. Agents Med. Chem., 2020, 20(18), 2150-2168.
[40]
Maruthanila, V.L.; Elancheran, R.; Kunnumakkar, A.B.; Kabilan, S. Kotoky, J Pleiotropic Effect of mahanine and girinimbine analogs: Anticancer mechanism and its therapeutic versatility. Anticancer. Agents Med. Chem., 2018, 18(14), 1983-1990.
[50]
Failli, A.A.; Steffan, R.J.; Kreft, A.F.; Caggiano, T.J.; Caufield, C.E. Pyranoindole and tetrahydrocarbazole inhibitors of COX-2. United States patent US 5,830,911, 1998.
[51]
Deng, W.; Chen, D.; Zhou, Y. Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (HDAC) inhibitors. PCT Int. Appl., 2006, WO2006101456, 28.
[53]
Lennox, W.; Qi, H.; Lee, D.H.; Choi, S.; Moon, Y.C. Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control. United States patent US 8,946,444, 2015.
[55]
Schuster, T.; Paulini, K.; Schmidt, P.; Baasner, S.; Polymeropoulos, E.; Guenther, E.; Teifel, M. Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors. United States patent US 8,148,546, 2012.
[56]
Paulini, K.; Gerlach, M.; Günther, E.; Polymeropoulos, E.; Baasner, S.; Schmidt, P.; Kühne, R.; Söderhäll, A. Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs). United States patent US 7,375,127, 2008.
[66]
Schaefer, K.L. PPARγ inhibitors as novel tubulin-targeting agents. PPAR Res., 2008, 2008, 785405.
[76]
Kumar, T.S.; Mahadevan, K.M.; Kumara, M.N. Synthesis and cytotoxic studies of 2, 3- dimethylindoles and tetrahydrocarbazoles. Int. J. Pharm. Pharm. Sci., 2014, 6(2), 137-140.
[78]
Chaudhary, M.; Chaudhary, P. Anticancer activity of microwave assisted newly synthesized 2, 3, 4, 9-tetrahydro-1h-carbazole derivatives. Int. J. Pharm. Pharm. Sci., 2016, 8(4), 390-392.
[83]
Lanka, S; Lakinani, V; Kakani, S.R.R. Evaluation of anti-cancer activity of N-substituted tetrahydrocarbazoles. Inter. J. Pharm. Anal. Res., 2017, 6(2)
[88]
Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell, 1995, 81(3), 323-330.
[97]
Gribble, G.W. The alkaloids; Academic Press: New York, USA, 1990.